Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10

Journal of Antibiotics

Volumn 66, Issue 10, 2013, Pages 625-627

  Pogue, Jason M ^a,b   Marchaim, Dror ^b,c,d   Abreu Lanfranco, Odaliz ^b   Sunkara, Bharath ^b   Mynatt, Ryan P ^a   Zhao, Jing J ^a   Bheemreddy, Suchitha ^b   Hayakawa, Kayoko ^b   Martin, Emily T ^a   Dhar, Sorabh ^b   Kaye, Keith S ^b   Lephart, Paul R ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

CRE; HAI; In vitro; Multidrug resistant; UTI; VRE

Indexed keywords

COLISTIN; FOSFOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTERIACEAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UNITED STATES; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENTEROCOCCUS; FOSFOMYCIN; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICHIGAN; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS; VANCOMYCIN RESISTANCE;

EID: 84886793958     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2013.56     Document Type: Article

References (28)

1. Chenoweth, C. E. & Saint, S. Urinary tract infections. Infect. Dis. Clin. North. Am. 25, 103-115 (2011).
2. Deshpande, L. M., Fritsche, T. R., Moet, G. J., Biedenbach, D. J. & Jones, R. N. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 58, 163-170 (2007). (Pubitemid 46856806)
3. Hidron, A. I. et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control. Hosp. Epidemiol. 29, 996-1011 (2008).
4. Goren, M. G., Navon-Venezia, S., Chmelnitsky, I. & Carmeli, Y. Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. Antimicrob. Agents. Chemother. 54, 2687-2691 (2010).
5. Peleg, A. Y. & Hooper, D. C. Hospital-acquired infections due to gram-negative bacteria. N Engl. J. Med. 362, 1804-1813 (2010).
6. Garau, J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin. Microbiol. Infect. 14 (Suppl 1), 198-202 (2008). (Pubitemid 350269204)
7. Hooton, T. M. et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 625-663 (2010).
8. Meddings, J., Rogers, M. A., Macy, M. & Saint, S. Systematic review and metaanalysis: reminder systems to reduce catheter-associated urinary tract infections and urinary catheter use in hospitalized patients. Clin. Infect. Dis. 51, 550-560 (2010).
9. Saint, S.et al. Preventing hospital-acquired urinary tract infection in the United States: a national study. Clin. Infect. Dis. 46, 243-250 (2008). (Pubitemid 351269163)
10. Boscia, J. A. et al. Lack of association between bacteriuria and symptoms in the elderly. Am. J. Med. 81, 979-982 (1986).
11. Tambyah, P. A. & Maki, D. G. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch. Intern. Med. 160, 678-682 (2000). (Pubitemid 30140418)
12. Kaye, K. S., Engemann, J. J., Mozaffari, E. & Carmeli, Y. Reference group choice and antibiotic resistance outcomes. Emerg. Infect. Dis. 10, 1125-1128 (2004). (Pubitemid 38697709)
13. Leavitt, A., Navon-Venezia, S., Chmelnitsky, I., Schwaber, M. J. & Carmeli, Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob. Agents. Chemother. 51, 3026-3029 (2007). (Pubitemid 47206254)
14. Endimiani, A. et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob. Agents. Chemother. 54, 526-529 (2010).
15. Falagas, M. E., Kastoris, A. C., Karageorgopoulos, D. E. & Rafailidis, P. I. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gramnegative bacilli: a systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents. 34, 111-120 (2009).
16. Patel, S. S., Balfour, J. A. & Bryson, H. M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a singledose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 53, 637-656 (1997). (Pubitemid 27145957)
17. Falagas, M. E., Kastoris, A. C., Kapaskelis, A. M. & Karageorgopoulos, D. E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect. Dis. 10, 43-50 (2010).
18. Neuner, E. A., Sekeres, J., Hall, G. S. & van Duin, D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob. Agents. Chemother. 56, 5744-5748 (2012).
19. Michalopoulos, A. et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect. 16, 184-186 (2010).
20. Wang, J. L. & Hsueh, P. R. Therapeutic options for infections due to vancomycinresistant enterococci. Expert. Opin. Pharmacother. 10, 785-796 (2009).
21. Institute CaLS. Performance standards for antimicrobial susceptibility testing. CLSI 29, 149 (2009).
22. Mirakhur, A., Gallagher, M. J., Ledson, M. J., Hart, C. A. & Walshaw, M. J. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J. Cyst. Fibros. 2, 19-24 (2003). (Pubitemid 36857405)
23. Falagas, M. E. et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 65, 1862-1877 (2010).
24. Pullukcu, H. et al. Fosfomycin in the treatment of extended spectrum beta-lactamaseproducing Escherichia coli-related lower urinary tract infections. Int. J. Antimicrob. Agents. 29, 62-65 (2007). (Pubitemid 44959781)
25. Senol, S. et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J. Chemother. 22, 355-357 (2010).
26. Shrestha, N. K. & Tomford, J. W. Fosfomycin: a review. Infect. Dis. Clin. Pract. 10, 255-260 (2001). (Pubitemid 33015187)
27. Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
28. Arca, P., Reguera, G. & Hardisson, C. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J. Antimicrob. Chemother. 40, 393-399 (1997). (Pubitemid 27437960)